Fact-checked by Grok 2 weeks ago

Sulforaphane

Sulforaphane is a naturally occurring isothiocyanate compound, classified as an organosulfur phytochemical, first isolated in 1992 from broccoli sprouts by Paul Talalay and colleagues at Johns Hopkins University, that forms through the enzymatic hydrolysis of its precursor glucoraphanin by the enzyme myrosinase in cruciferous vegetables. With the molecular formula C₆H₁₁NOS₂ and a molecular weight of 177.28 g/mol, it is a fat-soluble substance known for its high bioavailability, reaching up to 100% when consumed from food sources due to rapid absorption peaking within 1–3 hours after ingestion. Primarily found in Brassica species such as broccoli, broccoli sprouts, Brussels sprouts, cabbage, cauliflower, and kale, sulforaphane content is highest in the inflorescences and young sprouts of broccoli, where glucoraphanin concentrations can exceed 10 μmol/g dry weight. Sulforaphane exerts its biological effects primarily by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which upregulates the expression of phase II detoxification and antioxidant enzymes such as NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), and superoxide dismutase 1 (SOD1), thereby enhancing cellular defense against oxidative stress and electrophilic damage. This mechanism also contributes to its anti-inflammatory properties by suppressing nuclear factor kappa B (NF-κB) signaling and reducing pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Additionally, sulforaphane modulates epigenetic processes, including histone deacetylase inhibition, and induces apoptosis in damaged cells, supporting its role in disease prevention. Research highlights sulforaphane's potential health benefits across multiple systems, including chemoprevention of cancers such as , , and colorectal through inhibition of phase I carcinogen-activating enzymes and promotion of detoxification. It shows neuroprotective effects in models of ischemia, , and disorder by mitigating oxidative damage and inflammation in the . In metabolic contexts, sulforaphane aids in managing and cardiovascular conditions via Nrf2-mediated regulation of glucose homeostasis and reduction of . Antimicrobial and antidiabetic activities have also been documented, underscoring its broad therapeutic promise, though clinical translation requires further large-scale human trials to optimize dosing and delivery.

Chemistry

Structure and Nomenclature

Sulforaphane is an organosulfur with the molecular formula C₆H₁₁NOS₂. Its systematic IUPAC name is (R)-1-isothiocyanato-4-(methylsulfinyl), reflecting the chiral at the sulfur atom in the sulfinyl group. This naming convention highlights the key functional groups: the isothiocyanate (-N=C=S) moiety at the 1-position of the butane chain and the methylsulfinyl (-SOCH₃) at the 4-position. The molecular structure features a four-carbon aliphatic chain linking the electron-withdrawing group to the polar methylsulfinyl group, where the is in the +4 . This arrangement, depicted as CH₃-S(O)-(CH₂)₄-N=C=S, contributes to its reactivity and biological relevance. The (R)- is the naturally occurring form found in . Sulforaphane was first isolated and structurally elucidated in 1992 from ( var. italica) florets by Paul Talalay and colleagues at . It derives from the precursor via enzymatic hydrolysis, a process that releases the . This compound is primarily associated with , where it serves as a defense .

Physical and Chemical Properties

Sulforaphane is a colorless to pale yellow oil at room temperature. Its boiling point is approximately 125–135 °C at reduced pressure. The compound exhibits moderate solubility in water, approximately 2 mg/mL at 25 °C, and higher solubility in organic solvents such as ethanol (~10 mg/mL) and DMSO (~20 mg/mL). The (-N=C=S) imparts high chemical reactivity to sulforaphane, making it electrophilic at the central carbon and prone to nucleophilic attack by thiols or amines, which results in the formation of thioureas or related adducts. This reactivity contributes to its instability in aqueous solutions, where it undergoes degradation over time. Sulforaphane is sensitive to environmental factors including , , and exposure. It degrades more rapidly at neutral pH compared to acidic conditions, with a T90 of approximately 16 days in buffer at pH 5.0 and 26 °C. Elevated temperatures accelerate , with the rate increasing by a factor of about 3 for every 10 °C rise at pH 4.0. Spectroscopic techniques are useful for identifying sulforaphane. In () spectroscopy, a characteristic absorption band appears at approximately 2100 cm⁻¹ due to the asymmetric stretch of the group. (¹H NMR) shows key signals for the alkyl chain, including a triplet around 3.6 for the methylene protons adjacent to the . In (), the molecular ion is observed at m/z 177 (M⁺) or 178 ([M+H]⁺) in positive ion mode.

Natural Sources and Biosynthesis

Occurrence in Plants

Sulforaphane is present in primarily as its inactive precursor , a compound characteristic of the family, which includes various . This precursor is hydrolyzed by the enzyme upon tissue damage to yield active sulforaphane. Among these , exhibit the highest concentrations, reaching up to 1-3 mg/g fresh weight of (expressed as sulforaphane potential), which is 10- to 100-fold greater than in mature heads. Lower levels are found in mature (approximately 0.2-0.5 mg/g fresh weight), (around 0.1-0.3 mg/g), (0.1-0.5 mg/g), , and , with variations depending on specific cultivars and tissues. The concentration of glucoraphanin in these is influenced by factors such as plant age, genetic variety, and environmental growing conditions. Younger tissues, like 3-day-old sprouts, accumulate significantly higher levels than mature florets or heads, as glucoraphanin peaks early in before declining with plant maturation. selection plays a key role, with high-glucoraphanin varieties yielding up to several times more than standard types, while growing conditions like sulfur availability and practices may enhance content compared to conventional methods. Recent studies have shown that exogenous applications of or can further promote glucoraphanin accumulation by upregulating biosynthetic genes. Within the plant, is distributed unevenly, with the highest concentrations in , young sprouts, and leaves, where it serves as a protective . Roots contain absent or notably low levels, reflecting the 's role in aerial s rather than below-ground structures. Evolutionarily, functions as a in plants, deterring herbivores and pathogens through its products, which exhibit and repellency to deter feeding and .

Biosynthetic Pathway

Sulforaphane is produced in through the of its precursor, , which is an aliphatic synthesized via the amino acid-derived pathway starting from . The biosynthesis begins with chain elongation of in the and , where branched-chain aminotransferase 4 (BCAT4) converts to its corresponding α-keto acid, followed by methylthioalkylmalate 1 (MAM1) catalyzing the condensation with to form a malate intermediate. Subsequent steps involve isopropylmalate (AC1/AC2), β-keto acid reductoisomerase/dehydratase (DHAD), and 2-isopropylmalate (IPMDH) for iterative chain extension to dihomomethionine, with by BCAT3 yielding dihomomethionine, the precursor amino acid for the 4-carbon side chain in . The core glucosinolate structure is then formed at the surface, where monooxygenase CYP79F1 oxidizes the elongated derivative to an aldoxime, and CYP83A1 further converts it to an S-(hydroxyalkyl)thiohydroxamate intermediate, which is stabilized by conjugation with via glutathione S-transferases (GSTF11 and GGP1). This thiohydroximate is sulfated by sulfotransferase AtSOT16 or AtSOT17 to form the sulfonated derivative, followed by cleavage of the C-S bond by the C-S lyase SUR1 to yield the desulfoglucosinolate thiohydroximate. UDP-dependent UGT74B1 then adds a glucose moiety to form the thioglucoside, and finally, flavin-containing monooxygenases (FMO GS-OX1 to FMO GS-OX5) oxidize the terminal methylthio group to the methylsulfinyl group, completing glucoraphanin synthesis. Upon plant tissue damage, such as from chewing or crushing, glucoraphanin is activated to sulforaphane by the compartmentalized enzyme myrosinase (β-thioglucosidase, primarily TGG1 in Brassica species), which hydrolyzes the thioglucoside bond in a reaction requiring water. The hydrolysis proceeds as follows: \text{Glucoraphanin} + \text{H}_2\text{O} \rightarrow \text{Sulforaphane} + \text{D-glucose} + \text{SO}_4^{2-} This enzymatic cleavage releases the unstable aglycone, which spontaneously rearranges to the isothiocyanate sulforaphane, along with glucose and sulfate ions. The biosynthetic pathway, including production, is tightly regulated and upregulated in response to stresses such as herbivory, primarily through (JA) signaling that induces expression of key genes like those encoding CYP79F1, MAM1, and via transcription factors such as R2R3-MYB proteins. This stress-induced regulation enhances defense metabolite accumulation in cruciferous plants like .

Production Methods

Isolation from Natural Sources

Sulforaphane is primarily isolated from , particularly ( var. italica), which contain high levels of its inactive precursor, . The extraction process begins with the homogenization of fresh plant tissue, such as or seeds, in an aqueous medium at to activate the endogenous enzyme , which hydrolyzes to form sulforaphane. This enzymatic conversion is critical, as heating above 60°C inactivates and reduces yields. Following , the mixture undergoes to separate sulforaphane from the aqueous phase. Common solvents include or , which effectively partition the lipophilic sulforaphane while leaving behind polar impurities; alternatively, serves as a green method, avoiding organic solvents and preserving compound stability under controlled pressure and temperature conditions. The crude extract is then filtered to remove solid and . Purification typically involves chromatographic techniques, such as (SPE) using silica-based cartridges or (HPLC) with reverse-phase columns, to isolate sulforaphane from co-extracted compounds like other isothiocyanates and phenolics. The purified fraction is concentrated under reduced pressure or at low temperatures to prevent of the unstable sulforaphane molecule. Overall recovery rates from can exceed 90% with optimized SPE methods, though total yields vary based on plant material quality and processing conditions, with sprouts providing up to 10-fold higher sulforaphane potential than mature . Recent advances include biotechnological approaches, such as hairy root cultures of treated with elicitors like CuSO4 and ZnSO4, which have been shown to increase sulforaphane as of 2024. Additionally, extraction techniques, including ultrasound-assisted and microwave-assisted methods, have improved and in isolating sulforaphane from cruciferous sources up to 2025. In commercial production for dietary supplements, these methods are scaled up to produce standardized extracts, often containing 0.4% to 10% sulforaphane by weight, depending on the enrichment process and intended application. Such extracts are formulated into capsules or powders, ensuring through stabilization techniques like lyophilization or addition of stabilizers, and are widely used in nutraceuticals targeting health benefits. with proteins like or has emerged as a method to enhance and as of 2024.

Chemical Synthesis

Sulforaphane, chemically known as 1-isothiocyanato-4-(methylsulfinyl)butane, was first synthesized in the in 1948 by Schmid and Karrer through a multi-step process involving the preparation of the corresponding intermediate followed by conversion to the . This seminal work utilized the to install the amino group on the butyl chain, starting from a precursor, though specific yields were not reported in the original publication. Subsequent refinements in the and established this as the primary synthetic route, typically achieving overall yields of 20-40% across 5-7 steps, making it suitable for research-scale production. The standard laboratory synthesis begins with 1-bromo-4-chlorobutane, which undergoes with sodium methylthiolate (NaSCH₃) to form 1-chloro-4-(methylthio)butane in high yield (approximately 85-90%). This thioether is then oxidized selectively to the using m-chloroperbenzoic acid (mCPBA) or , yielding 1-chloro-4-(methylsulfinyl)butane with 70-80% efficiency while preserving the chain integrity. The is subsequently displaced by (KSCN) under heating in a polar , followed by thermal rearrangement to introduce the group, resulting in racemic sulforaphane with an overall process yield of around 30%. This route, detailed in patents and synthetic protocols, avoids toxic reagents like used in earlier variants. Alternative methods include the oxidation of the corresponding precursor, erucin (1-isothiocyanato-4-(methylthio)butane), which is prepared via from 1,4-dibromobutane, substitution with NaSCH₃, hydrazinolysis to the amine, and reaction with or safer equivalents like 1,1'-thiocarbonyldi-2,2'-pyridone (yields: 80% for erucin, 90% for subsequent oxidation to sulforaphane). For stereoselective production of the natural (R)-enantiomer, enantiodivergent approaches employ chiral auxiliaries or asymmetric oxidation, such as using chiral catalysts during formation, achieving enantiomeric excess >95% but with reduced overall yields (15-25%). Enzymatic routes using modified on synthetic precursors offer semi-synthetic options, though they are less common for pure . Key challenges in these syntheses involve handling volatile, lachrymatory intermediates like the , which require inert atmospheres and low temperatures to prevent decomposition, and ensuring stereocontrol at the chiral center without epimerization. A more recent four-step method starting from (tetrahydrothiophene) via ring-opening with , Staudinger-aza-Wittig reaction for formation, and oxidation provides an efficient alternative with 41% overall yield, bypassing phthalimide intermediates. These routes are primarily employed for preparing stable sulforaphane in and for formulating supplements where natural extraction proves inefficient or inconsistent.

Biological Activity

Mechanisms of Action

Sulforaphane primarily exerts its biological effects through activation of the Nrf2 signaling pathway. As an electrophilic , it covalently modifies , a negative regulator of Nrf2, by reacting with specific residues, such as C151. This modification disrupts the Keap1-Nrf2 interaction, inhibiting Nrf2 ubiquitination and proteasomal degradation, thereby allowing Nrf2 to translocate to the . The reaction involves nucleophilic attack by the thiol group of Keap1 cysteines on the central carbon of sulforaphane's moiety, forming a reversible . This can be represented as: \ce{R-N=C=S + R'-SH -> R-NH-C(=S)-S-R'} where R denotes the 4-(methylsulfinyl)butyl chain of sulforaphane and R' is the protein side chain. Nuclear Nrf2 then dimerizes with small Maf proteins and binds to the (ARE) in the promoter regions of target genes, upregulating and detoxifying enzymes such as NAD(P)H: 1 (NQO1) and S-transferases (). Beyond Nrf2, sulforaphane inhibits the pathway, which mediates inflammatory responses, by directly binding to essential residues in subunits, thereby suppressing their DNA-binding activity. It also functions as a (HDAC) inhibitor, promoting histone hyperacetylation and altering epigenetically. Nrf2 activation further induces phase II detoxification enzymes, enhancing cellular defense against xenobiotics and . At the cellular level, sulforaphane targets reactive thiols in proteins, leading to dose-dependent outcomes: low concentrations (e.g., 1–10 μM) trigger cytoprotective responses via , while higher doses (e.g., >50 μM) promote through excessive protein modification and . In cell models, sulforaphane uptake is rapid, with modification and Nrf2 nuclear accumulation occurring within 1–3 hours, reaching equilibrium shortly thereafter.

Metabolism and Bioavailability

Sulforaphane is rapidly absorbed in the following , with peak plasma concentrations typically occurring within 1-3 hours post-ingestion. , often measured by urinary excretion of metabolites, reaches approximately 70-90% when sulforaphane is consumed directly as supplements, but is substantially lower (around 2-45%) from food sources due to inefficiencies in the conversion from its precursor . Upon absorption, sulforaphane is quickly metabolized through the mercapturic acid pathway, beginning with conjugation to by glutathione S-transferases (GSTs) to form sulforaphane-. This conjugate undergoes sequential enzymatic modifications by γ-glutamyl-transpeptidase, cysteinylglycinease, and N-acetyltransferase, resulting in sulforaphane-cysteine and sulforaphane-N-acetylcysteine (SF-NAC) derivatives. These hydrophilic metabolites are primarily excreted in the , accounting for the majority of elimination, with a smaller portion via the . Several factors influence sulforaphane's and . The food matrix plays a key role, as enzyme activity—essential for hydrolyzing to sulforaphane—is preserved in raw but diminished by cooking or processing, leading to reduced yields. Additionally, interindividual variations in enzyme activity, often due to genetic polymorphisms such as in GSTM1, can alter conjugation rates and overall efficiency. Pharmacokinetically, sulforaphane exhibits an elimination of 2-6 hours, reflecting its rapid clearance. Tissue distribution favors high concentrations in the liver and , where and processes are most active.

Health Research

Anticancer Effects

Sulforaphane has demonstrated inhibitory effects on in preclinical models of various cancers, including , , and colon. In these models, sulforaphane induces through activation of pathways and mitochondrial dysfunction, leading to in cancer cells. It also promotes cell cycle arrest, particularly in the G2/M phase, by upregulating inhibitors such as p21 and downregulating cyclins, thereby halting proliferation. Additionally, sulforaphane suppresses by disrupting endothelial cell migration, tube formation, and microtubule polymerization, reducing (VEGF) expression and inhibiting new blood vessel formation essential for tumor growth. Epigenetic modifications, including altered patterns and (HDAC) inhibition, further contribute to these anticancer effects by reactivating tumor suppressor genes and silencing oncogenes. Clinical evidence from phase II trials supports sulforaphane's potential in cancer management, though results are mixed. In men with biochemical recurrence of after radical , daily oral sulforaphane (60 mg) for six months significantly slowed the rise in (PSA) levels, with a smaller mean increase in PSA levels over six months (0.099 ng/mL versus 0.620 ng/mL in controls; p=0.043) and PSA doubling time 86% longer in the treatment group (28.9 months versus 15.5 months). Another phase II study using sulforaphane-rich broccoli sprout extracts (200 μmol/day) in recurrent patients showed no major PSA declines but favorable changes in histone acetylation and reduced expression of progression genes like AMACR. For , short-term supplementation (100 μmol/day for 14 days) in women at high risk reduced Ki-67 proliferation index in tissue, though not statistically significant, alongside increased activity. Preclinical and early studies with broccoli sprout extracts have indicated reduced markers of progression, such as decreased cell viability and invasion in models, but dedicated clinical trials remain limited. A 2023 of randomized controlled trials confirmed sulforaphane's chemopreventive potential through modulation across cancers, including changes related to epithelial-mesenchymal transition and . These anticancer effects are partly mediated by sulforaphane's activation of the Nrf2 pathway, which enhances phase II detoxification enzymes like , reducing damage from environmental carcinogens. In smokers, sprout extracts rich in sulforaphane increased urinary excretion of tobacco-specific carcinogens like NNAL by up to 3.5-fold, demonstrating enhanced detoxification. Similarly, in aflatoxin-exposed models, sulforaphane reduced formation ( B1-N7-guanine) by 50-64% via GST induction, lowering risk. Despite promising data, most evidence derives from small, observational, or phase II trials with heterogeneous dosing and short durations; no large-scale phase III trials have established sulforaphane as a standard treatment, highlighting the need for further validation.

Neurological and Anti-Inflammatory Benefits

Sulforaphane exhibits neuroprotective effects in preclinical models of neurological disorders, primarily through activation of the Nrf2 pathway, which enhances antioxidant defenses and reduces in the brain. In models of autism spectrum disorder (ASD), (AD), and (PD), sulforaphane-mediated Nrf2 activation has been shown to mitigate neuronal damage and improve synaptic function by upregulating genes involved in synthesis and detoxification. A 2025 study demonstrated that sulforaphane protects developing human cortical neural networks from valproic acid-induced synaptic alterations, preserving network activity and formation during critical developmental windows. Sulforaphane also displays potent anti-inflammatory properties by suppressing signaling in macrophages and other immune cells, thereby reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. This mechanism has shown therapeutic potential in animal models of , where sulforaphane alleviated and , and in (IBD) models, where it inhibited activation and colonic . Clinical evidence supports sulforaphane's benefits in neurological conditions. In randomized controlled trials for conducted between 2014 and the early 2020s, sulforaphane supplementation in children led to significant improvements in behavior scores, including enhanced interaction, reduced irritability, and better verbal communication, as measured by tools like the Aberrant Behavior Checklist and Social Responsiveness Scale. As an adjunct to antipsychotics in , high-dose sulforaphane reduced negative symptoms, such as withdrawal and blunted , over 24 weeks in a 2025 trial, with good tolerability. Ongoing clinical studies in 2024-2025 are investigating sulforaphane's role in (TBI), building on preclinical data showing improved cognitive outcomes post-injury through Nrf2-mediated . Through the gut-brain axis, sulforaphane modulates composition to promote the production of anti-inflammatory metabolites, such as , which may contribute to alleviating symptoms of mood disorders like . This microbiota-mediated effect enhances barrier integrity and reduces , linking dietary sulforaphane intake to improved emotional regulation.

Other Potential Applications

Sulforaphane has demonstrated potential in enhancing detoxification processes by inducing phase II enzymes, such as S-transferase () and NAD(P)H: 1 (NQO1), which facilitate the conjugation and elimination of environmental toxins including like and . In animal models, sulforaphane activates the Nrf2 pathway to mitigate and tissue damage from chromium exposure, reducing lung and cardiac toxicity at doses of 4 mg/kg/day. Similar protective effects extend to other , such as arsenic-induced , through upregulation of defenses and inhibition of . Preliminary also suggests benefits against pesticide-related oxidative damage, though human data remain limited. In clinical contexts, sulforaphane supplementation has shown promise in reducing oxidative damage among schizophrenia patients, a population vulnerable to environmental toxin accumulation. An open-label trial involving sulforaphane-rich broccoli sprout extract (100 μmol/day for 8 weeks) improved cognitive function and antioxidant status, potentially by normalizing Nrf2-mediated defenses against oxidative stress. Mechanisms involve enhanced glutathione levels and reduced neuroinflammation, supporting detoxification in this high-risk group. Regarding cardiovascular applications, sulforaphane exhibits antihypertensive effects in animal models of , such as stroke-prone spontaneously hypertensive rats, where daily administration (0.5 mg/kg for over 3 months) normalized through Nrf2-dependent endothelial protection and reduced oxidative vascular damage. Small human studies corroborate these findings, with sprout extracts yielding sulforaphane (equivalent to 100-200 μmol/day) lowering systolic by 5-10 mmHg in individuals with mild over 4-12 weeks, via improved vascular function. In metabolic health, sulforaphane improves insulin sensitivity in models by suppressing hepatic through Nrf2 nuclear translocation, as evidenced in high-fat diet-fed where it enhanced glucose tolerance and reduced fasting blood glucose levels comparably to metformin. Recent 2023-2024 research highlights its role in modulating to combat ; for instance, supplementation (precursor to sulforaphane, 30 μmol/day for 12 weeks) in high-fat diet models increased beneficial bacteria like , reduced body weight by 10-15%, and improved insulin sensitivity via altered short-chain production. A 2024 study further confirmed these microbiota shifts attenuate metabolic endotoxemia in obese mice. Sulforaphane holds potential for respiratory conditions like and (COPD) through anti-inflammatory mechanisms. In a randomized of 44 asthmatic patients, daily broccoli sprout homogenate (providing ~150 μmol sulforaphane for 3 days) enhanced bronchoprotective responses to challenge, increasing Nrf2-regulated and reducing airway markers by 20-30%. Preliminary COPD trials indicate reduced exacerbation frequency with sulforaphane supplementation (100-200 μmol/day for 8 weeks), linked to lowered neutrophilic , though larger studies are needed. Emerging 2024 research explores sulforaphane's applications in skin health and aging. Topical or oral sulforaphane mobilizes phase II enzymes to protect against UV-induced damage, as shown in human and mouse models where broccoli sprout extracts (1-10 nmol/cm²) reduced erythema and DNA adducts by up to 50% via Nrf2 activation. A 2024 systematic review of animal studies affirmed its role in preventing UV-related skin carcinogenesis through antioxidant and anti-proliferative effects. For aging, sulforaphane supports telomere maintenance by activating Nrf2 to counteract oxidative telomere shortening; in vitro studies demonstrate epigenetic modulation of telomerase activity, preserving length in aging cells. Recent 2024 analyses link this to broader anti-aging benefits in Nrf2-deficient models.

Safety and Dietary Considerations

Toxicity and Side Effects

Sulforaphane demonstrates low in preclinical models. In mice, the (LD50) following intraperitoneal administration is approximately 212 mg/kg, indicating a relatively high for compared to typical therapeutic doses. No serious adverse events have been observed in human clinical trials at oral doses up to 200 µmol (approximately 35 mg) per day, with administration durations extending to 6 months in some studies. Common side effects of sulforaphane supplementation are mild and primarily gastrointestinal, including gas, , , , , and , which occur more frequently at higher doses exceeding 100 mg daily. These effects are typically grade 1 or 2 in severity and resolve without intervention. Rare allergic reactions, such as or , have been reported in sensitive individuals, though overall tolerability remains high across diverse populations in randomized controlled trials. Chronic exposure to sulforaphane appears safe based on available data from 12-week and longer clinical trials, where no significant accumulation of adverse effects was noted. Preclinical assessments show no in assays or carcinogenicity in animal models, supporting its profile as a non-mutagenic compound. Regarding interactions, sulforaphane may exhibit goitrogenic potential at very high intakes from raw cruciferous sources due to interference with iodine uptake, warranting monitoring in patients with ; however, this risk is minimized with adequate iodine intake, and clinical studies with sprout-derived sulforaphane have confirmed no disruption to function or renal markers at standard doses. The U.S. Food and Drug Administration (FDA) recognizes sulforaphane as safe for food use through its natural occurrence in cruciferous vegetables, with the precursor glucoraphanin granted Generally Recognized as Safe (GRAS) status for incorporation into food products. Dietary supplements containing sulforaphane, however, fall under less stringent regulation and are not evaluated for efficacy or purity by the FDA.

Intake Recommendations

Sulforaphane is primarily obtained through the consumption of , where it forms from the precursor upon the action of the . Health organizations, including the and the , recommend incorporating 3-5 servings (approximately 350-500 grams) of per week as part of a balanced diet to support potential benefits, with serving as a particularly concentrated source yielding about 20-50 mg of sulforaphane per 100 grams of fresh weight. To maximize sulforaphane yield from dietary sources, should be consumed or lightly steamed for 1-3 minutes to preserve activity, as higher heat can inactivate the and reduce by up to 90%. Chopping or chewing the thoroughly and allowing them to sit for 10-40 minutes before cooking activates and enhances sulforaphane formation; adding a small amount of or powder can further boost conversion if the is compromised by cooking. Methods like or microwaving should be avoided, as they significantly diminish sulforaphane content compared to or . For those seeking higher or more consistent intake, sulforaphane supplements derived from stabilized extracts are available, with typical dosing ranging from 20-100 mg per day, which is roughly equivalent to the sulforaphane yield from 1-2 cups (100-200 grams) of fresh . There is no established Recommended Dietary Allowance (RDA) for sulforaphane, but research from clinical trials suggests a daily intake of 10-40 µmol (approximately 1.8-7 mg) may provide beneficial effects, with higher doses up to 100 µmol used in studies for therapeutic purposes. Individuals with higher toxin exposure, such as smokers or former smokers, may benefit from increased intake to support pathways, as evidenced by phase II s showing enhanced clearance of carcinogens like with daily sprout consumption. A 2025 published in Nature Microbiology demonstrated benefits of sprout extract for management, highlighting the role of in sulforaphane efficacy.